The estimated Net Worth of Bioventures 2018, L.P.Mpm B... is at least $72.9 millió dollars as of 4 January 2022. Bioventures B owns over 146,685 units of iTeos Therapeutics stock worth over $43,793,172 and over the last 4 years Bioventures sold ITOS stock worth over $29,129,167.
Bioventures has made over 18 trades of the iTeos Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently Bioventures sold 146,685 units of ITOS stock worth $6,245,847 on 4 January 2022.
The largest trade Bioventures's ever made was selling 146,685 units of iTeos Therapeutics stock on 4 January 2022 worth over $6,245,847. On average, Bioventures trades about 50,289 units every 15 days since 2021. As of 4 January 2022 Bioventures still owns at least 2,738,785 units of iTeos Therapeutics stock.
You can see the complete history of Bioventures B stock trades at the bottom of the page.
Over the last 4 years, insiders at iTeos Therapeutics have traded over $196,492,023 worth of iTeos Therapeutics stock and bought 4,975,000 units worth $95,182,800 . The most active insiders traders include Capital Management, L.P.Ra ..., Capital Management, L.P.Kol... és Aaron I. Davis. On average, iTeos Therapeutics executives and independent directors trade stock every 12 days with the average trade being worth of $1,817,279. The most recent stock trade was executed by Matthew Gall on 12 October 2023, trading 5,000 units of ITOS stock currently worth $41,850.
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.
iTeos Therapeutics executives and other stock owners filed with the SEC include: